232 related articles for article (PubMed ID: 36325361)
1. Roles of follistatin-like protein 3 in human non-tumor pathophysiologies and cancers.
Tian S; Xu X; Yang X; Fan L; Jiao Y; Zheng M; Zhang S
Front Cell Dev Biol; 2022; 10():953551. PubMed ID: 36325361
[TBL] [Abstract][Full Text] [Related]
2. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
3. Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.
Brown ML; Bonomi L; Ungerleider N; Zina J; Kimura F; Mukherjee A; Sidis Y; Schneyer A
Obesity (Silver Spring); 2011 Oct; 19(10):1940-9. PubMed ID: 21546932
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 9 (GDF9) suppresses follistatin and follistatin-like 3 production in human granulosa-lutein cells.
Shi FT; Cheung AP; Huang HF; Leung PC
PLoS One; 2011; 6(8):e22866. PubMed ID: 21829661
[TBL] [Abstract][Full Text] [Related]
5. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
Stamler R; Keutmann HT; Sidis Y; Kattamuri C; Schneyer A; Thompson TB
J Biol Chem; 2008 Nov; 283(47):32831-8. PubMed ID: 18768470
[TBL] [Abstract][Full Text] [Related]
6. Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice.
Ozawa T; Morikawa M; Morishita Y; Ogikubo K; Itoh F; Koinuma D; Nygren PÅ; Miyazono K
iScience; 2021 May; 24(5):102488. PubMed ID: 34113826
[TBL] [Abstract][Full Text] [Related]
7. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.
Mukherjee A; Sidis Y; Mahan A; Raher MJ; Xia Y; Rosen ED; Bloch KD; Thomas MK; Schneyer AL
Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1348-53. PubMed ID: 17229845
[TBL] [Abstract][Full Text] [Related]
8. Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy.
Shimano M; Ouchi N; Nakamura K; Oshima Y; Higuchi A; Pimentel DR; Panse KD; Lara-Pezzi E; Lee SJ; Sam F; Walsh K
J Biol Chem; 2011 Mar; 286(11):9840-8. PubMed ID: 21245136
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of follistatin-like 3 in human invasive breast cancer.
Couto HL; Buzelin MA; Toppa NH; Bloise E; Wainstein AJ; Reis FM
Oncotarget; 2017 Jun; 8(26):42189-42197. PubMed ID: 28178680
[TBL] [Abstract][Full Text] [Related]
10. Differential actions of follistatin and follistatin-like 3.
Schneyer A; Sidis Y; Xia Y; Saito S; del Re E; Lin HY; Keutmann H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):25-8. PubMed ID: 15451564
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice.
Brandt C; Hansen RH; Hansen JB; Olsen CH; Galle P; Mandrup-Poulsen T; Gehl J; Pedersen BK; Hojman P
Metabolism; 2015 Feb; 64(2):283-95. PubMed ID: 25456456
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.
McCoy JC; Walker RG; Murray NH; Thompson TB
J Biol Chem; 2019 Apr; 294(16):6333-6343. PubMed ID: 30814254
[TBL] [Abstract][Full Text] [Related]
13. FSTL3-Neutralizing Antibodies Enhance Glucose-Responsive Insulin Secretion in Dysfunctional Male Mouse and Human Islets.
Brown ML; Lopez A; Meyer N; Richter A; Thompson TB
Endocrinology; 2021 Oct; 162(10):. PubMed ID: 33539535
[TBL] [Abstract][Full Text] [Related]
14. Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.
Cash JN; Angerman EB; Kattamuri C; Nolan K; Zhao H; Sidis Y; Keutmann HT; Thompson TB
J Biol Chem; 2012 Jan; 287(2):1043-53. PubMed ID: 22052913
[TBL] [Abstract][Full Text] [Related]
15. Follistatin-like 3, an activin A binding protein, is involved in early pregnancy loss.
Xu Y; Xie J; Wan L; Wang M; Xu Y; Wang H; Dong M
Biomed Pharmacother; 2020 Jan; 121():109577. PubMed ID: 31810141
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of FSTL3, ADAM12, and FAT4 in Patients of Colon Cancer: Clinicopathologic Study.
Ibrahim HM; Abdelrahman AE; Elwan A; Bakry A; Fahmy MM; Abdelhamid MI; Abdelwanis AH; Fouad EM
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):673-681. PubMed ID: 37751246
[TBL] [Abstract][Full Text] [Related]
17. Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.
Oldknow KJ; Seebacher J; Goswami T; Villen J; Pitsillides AA; O'Shaughnessy PJ; Gygi SP; Schneyer AL; Mukherjee A
Endocrinology; 2013 Mar; 154(3):1310-20. PubMed ID: 23407452
[TBL] [Abstract][Full Text] [Related]
18. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.
Panse KD; Felkin LE; López-Olañeta MM; Gómez-Salinero J; Villalba M; Muñoz L; Nakamura K; Shimano M; Walsh K; Barton PJ; Rosenthal N; Lara-Pezzi E
J Cardiovasc Transl Res; 2012 Dec; 5(6):814-26. PubMed ID: 22915069
[TBL] [Abstract][Full Text] [Related]
19. Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor.
Robertson RD; Mukherjee A
Biochem Biophys Res Commun; 2012 Oct; 427(3):568-73. PubMed ID: 23022195
[TBL] [Abstract][Full Text] [Related]
20. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.
Cash JN; Angerman EB; Keutmann HT; Thompson TB
Mol Endocrinol; 2012 Jul; 26(7):1167-78. PubMed ID: 22593183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
